RxDoctor Payments Data

Evelyn Wright

Family Health · Lawrenceburg, TNNPI 1376777508

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 33.6% of the total.

$1,658in general payments, 2019–2025

Across 122 payments — averaging $13.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$557
  • Novo Nordisk$268
  • AstraZeneca$227
  • GSK$109
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$67
  • Bayer$63
  • plus $366 from 13 others

What the payments were for

  • Food & beverage$1,658100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few family health providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$72,925
Medicare patients
297
Services billed
2,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol33$28,338
LinzessLinaclotide21$20,837
TrulicityDulaglutide14$19,087
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$16,716
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen221$5,539
Solifenacin Succinate11$3,493
Albuterol Sulfate HfaAlbuterol Sulfate53$1,551
SynthroidLevothyroxine Sodium16$1,416
Omeprazole110$1,378
Naloxone Hcl23$1,348
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav140$1,264
Gabapentin84$929
Pregabalin38$856
Atorvastatin Calcium61$736
Lidocaine12$674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$227$28,33833 claims
AbbVieLinzess, Synthroid$557$22,25437 claims
Lilly USA, LLCTrulicity$48$19,08714 claims
GSKTrelegy Ellipta$109$16,71615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in Tennesseeon file to place this against a meaningful peer group, so we don't.

Other family health in Lawrenceburg

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →